{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:07:31Z","timestamp":1775009251311,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08737"],"award-info":[{"award-number":["20K08737"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K07863"],"award-info":[{"award-number":["23K07863"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtct.2025.01.882","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T14:33:38Z","timestamp":1737210818000},"page":"253.e1-253.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low Survival Due to Higher Risk of Relapse and Nonrelapse Mortality After Allogeneic HSCT in ATL Compared with AML and ALL"],"prefix":"10.1016","volume":"31","author":[{"given":"Shohei","family":"Tomori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7391-4271","authenticated-orcid":false,"given":"Satoko","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-4585","authenticated-orcid":false,"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-9315","authenticated-orcid":false,"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sawayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-1720","authenticated-orcid":false,"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-0385","authenticated-orcid":false,"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2025.01.882_bib0001","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.882_bib0002","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1073\/pnas.78.10.6476","article-title":"Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera","volume":"78","author":"Hinuma","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.882_bib0003","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the lymphoma study group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"34","key":"10.1016\/j.jtct.2025.01.882_bib0004","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.882_bib0005","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.882_bib0006","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.jtct.2025.01.882_bib0007","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult t-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.882_bib0008","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/cas.15431","article-title":"Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results","volume":"113","author":"Utsunomiya","year":"2022","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.882_bib0009","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.882_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","article-title":"Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma: a case report and review of the literature","volume":"23","author":"Tsukasaki","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.882_bib0011","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41409-021-01412-9","article-title":"Long-term follow-up of patients with ATL after autologous stem cell transplantation","volume":"57","author":"Utsunomiya","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.882_bib0012","first-page":"441","article-title":"Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation","volume":"2","author":"Sobue","year":"1987","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.882_bib0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","article-title":"Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Utsunomiya","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.882_bib0014","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.882_bib0015","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","article-title":"Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study","volume":"120","author":"Ishida","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.882_bib0016","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12185-018-02588-5","article-title":"JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma","volume":"109","author":"Tsukasaki","year":"2019","journal-title":"Int J Hematol"},{"issue":"20","key":"10.1016\/j.jtct.2025.01.882_bib0017","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/bloodadvances.2021004932","article-title":"Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study","volume":"5","author":"Ito","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.882_bib0018","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41409-018-0139-z","article-title":"Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia\/lymphoma","volume":"53","author":"Inoue","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.882_bib0019","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.bbmt.2017.11.005","article-title":"Risk assessment in adult T cell leukemia\/lymphoma treated with allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Yoshimitsu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.882_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bmt.2015.265","article-title":"Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma","volume":"51","author":"Fuji","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.882_bib0021","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41409-019-0669-z","article-title":"Transplant-related complications are impediments to the success of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia patients in non-complete remission","volume":"55","author":"Tomori","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.882_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.882_bib0023","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/v14040791","article-title":"Nationwide hospital-based survey of adult T-cell leukemia\/lymphoma in Japan","volume":"14","author":"Kato","year":"2022","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.882_bib0024","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2025.01.882_bib0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/bmt.2012.282","article-title":"Suggestions on the use of statistical methodologies in studies of the European group for blood and marrow transplantation","volume":"48","author":"Iacobelli","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.882_bib0026","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression model and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"446","key":"10.1016\/j.jtct.2025.01.882_bib0027","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.882_bib0028","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.882_bib0029","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.882_bib0030","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.jtct.2025.01.882_bib0031","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.882_bib0032","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bbmt.2014.02.014","article-title":"High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia","volume":"20","author":"Shigematsu","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.882_bib0033","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bmt.2010.92","article-title":"Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: results of prospective trials","volume":"46","author":"Choi","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.882_bib0034","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1038\/s41409-021-01445-0","article-title":"Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma","volume":"56","author":"Inoue","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.882_bib0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hon.2558","article-title":"The outcome and characteristics of patients with relapsed adult T cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Kato","year":"2019","journal-title":"Hematol Oncol"},{"issue":"28","key":"10.1016\/j.jtct.2025.01.882_bib0036","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult t-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.882_bib0037","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.882_bib0038","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hon.3115","article-title":"Lenalidomide treatment for recurrent adult T-cell leukemia\/lymphoma after allogeneic hematopoietic cell transplantation","volume":"41","author":"Tanaka","year":"2022","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.882_bib0039","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1158\/1078-0432.CCR-13-3169","article-title":"CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia\/lymphoma","volume":"20","author":"Kobayashi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.882_bib0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-021-00458-8","article-title":"Quantification of T cell clonality in human T cell leukaemia virus type-1 carriers can detect the development of adult T cell leukaemia early","volume":"11","author":"Wolf","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.882_bib0041","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13302","article-title":"Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study","volume":"169","author":"Suehiro","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2025.01.882_bib0042","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3389\/fmicb.2020.01207","article-title":"Diagnostic approaches and established treatments for adult T cell leukemia lymphoma","volume":"11","author":"Tsukasaki","year":"2020","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.882_bib0043","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.bbmt.2013.01.011","article-title":"Distinct clinical features of infectious complications in adult T cell leukemia\/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group","volume":"19","author":"Itonaga","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.882_bib0044","doi-asserted-by":"crossref","first-page":"928.e1","DOI":"10.1016\/j.jtct.2021.07.010","article-title":"A phase I\/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia\/lymphoma","volume":"27","author":"Tanaka","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.882_bib0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.19835","article-title":"Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia\/lymphoma","volume":"206","author":"Yoshimitsu","year":"2025","journal-title":"Br J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725009091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725009091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:52:31Z","timestamp":1775004751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725009091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666636725009091"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.882","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Survival Due to Higher Risk of Relapse and Nonrelapse Mortality After Allogeneic HSCT in ATL Compared with AML and ALL","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}